Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P990004/S076

SURGIFOAM Absorbable Gelatin Sponge

Ferrosan Meidcal Devices A/S · Decision date Sep 8, 2025

FDA DECISIONP990004/S076

What did the FDA decide?

FDA records P990004/S076 as a supplement to PMA P990004, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 8, 2025.

FDA approval order statement

the implementation of an additional Syringe Assembly machine to increase production capacity for SURGIFLOW Hemostatic Matrix Kit and SURGIFLOW Hemostatic Matrix Kit with Thrombin productsThe proposed change qualifies for 30-Day Notice because it involves: Implementation and use of an additional Syringe Assembly machine. Manufacturing method/process change only. Capacity increase for existing products.This manufacturing change meets FDA criteria for 30-Day Notice submission because it's a manufacturing capacity addition that maintains identical product specifications without impacting intended device safety, effectiveness, or characteristics. The change is operational (additional assembly location) rather than modification (product alteration).
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Sep 8, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P990004/S076
Regulatory pathway
PMA supplement
Product code
LMF
Decision code
OK30
Decision date
Sep 8, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, collagen based.

Product code
LMF
FDA device class
3

For the original device and its historical approval scope, see PMA P990004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P990004 · Original PMA

    SURGIFOAM ABSORBABLE GELATIN SPONGE, USP

  2. P990004/S075 · Related supplement

    SURGIFLO Hemostatic Matrix; SURGIFLO Hemostatic Matrix Kit with Thrombin

  3. P990004/S076 received

    Application receipt date recorded by FDA.

  4. P990004/S076 · FDA decision

    30-Day Notice

  5. P990004/S077 · Related supplement

    SURGIFOAM Absorbable Gelatin Sponge, USP

  6. P990004/S078 · Related supplement

    SURGIFOAM Absorbable Gelatin Sponge

  7. P990004/S079 · Related supplement

    SURGIFOAM Absorbable Gelatin Sponge

  8. P990004/S081 · Related supplement

    SURGIFOAM Absorbable Gelatin Sponge

  9. P990004/S080 · Related supplement

    SURGIFOAM Absorbable Gelatin Sponge

Timeline entries are records held by MedtechLedger for P990004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P990004

Explore the linked device profile

Other records with product code LMF

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ferrosan Meidcal Devices A/S

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Sydmarken 5, Soeborg, 08876

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records